CompletedNot Applicable

The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection

South Korea100 participantsStarted 2016-06-02

Plain-language summary

Surgical stress and anesthesia may cause immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. Dexmedetomidine has sympatholytic effect and preserves NK cell function. This study investigate the effect of dexmedetomidine on immune suppression and postoperative outcomes in patients undergoing uterine cancer resection.

Who can participate

Age range20 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patient between 20 and 70 of age with ASA physical status Ⅰ-Ⅲ * patient scheduled for uterine cancer surgery Exclusion Criteria: * ASA physical status Ⅳ * severe hepatorenal disease * infection * metastasis to other organ * problem with communication

What they're measuring

natural killer cell cytotoxicity

Timeframe: 1 minute before surgery

natural killer cell cytotoxicity

Timeframe: postoperative day 1

natural killer cell cytotoxicity

Timeframe: postoperative day 3

natural killer cell cytotoxicity

Timeframe: postoperative day 5

Trial details

NCT IDNCT02896413

SponsorYonsei University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-10-24

View on ClinicalTrials.gov More Uterine Cancer trials